HSC Committee announces further ‘Availability of Orkambi on the NHS’ evidence session

The Health and Social Care (HSC) Committee has announced that it will hold a further oral evidence session in its Availability of Orkambi on the NHS inquiry.

A debate on this issue was held in Parliament at the start of this month.

Witnesses at the evidence session will include:

  • A patient representative nominated by the Cystic Fibrosis Trust
  • A clinician representative nominated by the Cystic Fibrosis Trust
  • A representative from NHS England
  • A representative from NICE
  • Dr Jeff Leiden, Chairman, President and Chief Executive Officer, Vertex Pharmaceuticals
  • Stuart A. Arbuckle, Executive Vice President and Chief Commercial Officer, Vertex Pharmaceuticals

The evidence session will be held on 07 March 2019 at 10:15am.

Tagged with

Published 1. March 2019 in News UK